Financial Survey: Spectral AI (MDAI) and Its Rivals

Spectral AI (NASDAQ:MDAI) is one of 159 publicly-traded companies in the “Medical Devices” industry, but how does it contrast to its competitors? We will compare Spectral AI to similar businesses based on the strength of its profitability, analyst recommendations, valuation, earnings, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Spectral AI and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$22.53 million	-$20.85 million	-0.96
Spectral AI Competitors	$895.60 million	$66.42 million	102.71

Spectral AI’s competitors have higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Spectral AI and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-299.42%	-147.81%	-24.18%

Institutional and Insider Ownership

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 31.6% of shares of all “Medical Devices” companies are held by institutional investors. 56.7% of Spectral AI shares are held by company insiders. Comparatively, 24.7% of shares of all “Medical Devices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Spectral AI and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	381	1543	2174	102	2.48

Spectral AI currently has a consensus price target of $4.50, indicating a potential upside of 248.84%. As a group, “Medical Devices” companies have a potential upside of 199.29%. Given Spectral AI’s stronger consensus rating and higher probable upside, research analysts clearly believe Spectral AI is more favorable than its competitors.

Volatility and Risk

Spectral AI has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s competitors have a beta of 0.88, indicating that their average share price is 12% less volatile than the S&P 500.

Summary

Spectral AI beats its competitors on 8 of the 13 factors compared.

Spectral AI Company Profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.